Clinical-stage company developing breakthrough multi-specific biologics to enhance patient outcomes across autoimmune, oncological, and other immunological disorders
About us
Novalgen is a clinical-stage company, revolutionizing the immunology landscape with its innovative autoregulation technology. Our focus is on the next generation of multi-specific antibodies to generate transformative outcomes in autoimmune, oncological, and other immunological disorders.
Our technologies
We are changing the paradigm of immunotherapies with our autoregulation platform technology. This groundbreaking approach integrates self-regulating capabilities into a range of immunotherapies tailored to improve clinical outcomes in patients.
Pipeline
To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.
